Literature DB >> 7731343

Clofazimine induced cardiotoxicity--a case report.

S H Choudhri1, L Harris, J W Butany, J S Keystone.   

Abstract

A 66-year-old Indian male who had been treated for recurrent erythema nodosum leprosum with 300 mg of clofazimine per day for 11 months presented to hospital with a 4 week history of severe gastrointestinal upset. Soon after admission he developed several short runs of ventricular tachycardia with a morphology suggestive of torsade de pointe. The patient had a slightly low magnesium level which was corrected within 2 days; however, his rhythm disturbance persisted for 5 days despite management with intravenous lidocaine. His gastrointestinal symptoms abated 2 weeks after clofazimine was discontinued. Subsequent investigations showed that the patient had a keratopathy and myelin-type figures in his polymorphonuclear white cells similar to that seen with the cardiotoxic drugs chloroquine and amiodarone. It is postulated that clofazimine alone or in conjunction with electrolyte disturbance was responsible for the patient's cardiac arrythmia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731343     DOI: 10.5935/0305-7518.19950009

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

1.  Safety of prolonged treatment with bedaquiline in programmatic conditions.

Authors:  Dzmitriy Zhurkin; Elmira Gurbanova; Jonathon R Campbell; Dick Menzies; Svetlana Setkina; Hennadz Hurevich; Varvara Solodovnikova; Dzmitry Viatushka; Alan Altraja; Alena Skrahina
Journal:  ERJ Open Res       Date:  2022-05-16

2.  Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.

Authors:  Mahmoud Tareq Abdelwahab; Richard Court; Daniel Everitt; Andreas H Diacon; Rodney Dawson; Elin M Svensson; Gary Maartens; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro.

Authors:  Ronald Anderson; Annette J Theron; Jan G Nel; Chrisna Durandt; Moloko C Cholo; Charles Feldman; Gregory R Tintinger
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

4.  Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.

Authors:  Tomohiro Sasaki; Elin M Svensson; Xiaofeng Wang; Yanlin Wang; Jeffrey Hafkin; Mats O Karlsson; Suresh Mallikaarjun
Journal:  Antimicrob Agents Chemother       Date:  2021-11-29       Impact factor: 5.191

5.  QT prolongation in the STREAM Stage 1 Trial.

Authors:  G Hughes; H Bern; C-Y Chiang; R L Goodall; A J Nunn; I D Rusen; S K Meredith
Journal:  Int J Tuberc Lung Dis       Date:  2022-04-01       Impact factor: 2.373

6.  WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?

Authors:  Nirmal Kumar Jain
Journal:  Lung India       Date:  2021 Jul-Aug

Review 7.  Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.

Authors:  Francesco Pecora; Giulia Dal Canto; Piero Veronese; Susanna Esposito
Journal:  Microorganisms       Date:  2021-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.